SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Triazolam Tablets
Trade Name: HALCION; Semese
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used for insomnia.

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification
Reproductive Toxicity: Category 1B : Effects on or via lactation

EU Classification:
EU Indication of danger: Toxic to Reproduction: Category 2

EU Risk Phrases:
R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.

Label Elements

Signal Word: Danger
Hazard Statements:
H360D - May damage the unborn child
H362 - May cause harm to breast-fed children

Precautionary Statements:
P201 - Obtain special instructions before use
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P263 - Avoid contact during pregnancy/while nursing
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
Other Hazards
Australian Hazard Classification (NOHSC):

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triazolam</td>
<td>28911-01-5</td>
<td>249-307-3</td>
<td>R64</td>
<td>Lact. (H362)</td>
<td>0.1 - 1</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Silicon dioxide, NF</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Corn Starch</td>
<td>9005-25-6</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Docusate Sodium</td>
<td>577-11-7</td>
<td>209-406-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>532-32-1</td>
<td>208-534-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures
Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical product used for insomnia
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Triazolam

Pfizer OEL TWA-8 Hr: 0.8µg/m³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³
Silicon dioxide, NF

OSHA - Final PELs - Table Z-3 Mineral D: 20 mppcf

Listed

Magnesium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Corn Starch

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Analytical Method:
Analytical method available for triazolam. Contact Pfizer Inc for further information.

Exposure Controls:
Engineering Controls:
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:
Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:
Wear safety glasses or goggles if eye contact is possible.

Skin:
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:
If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:
Tablet

Color:
White, blue.

Odor:
No data available.

Odor Threshold:
No data available.

Molecular Formula:
Mixture

Molecular Weight:
Mixture

Solvent Solubility:
No data available

Water Solubility:
No data available

pH:
No data available.

Melting/Freezing Point (°C):
No data available

Boiling Point (°C):
No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)
Triazolam
Predicted 7.4 Log D 8.175

Lactose
No data available

Microcrystalline cellulose
No data available

Silicon dioxide, NF
No data available

Docusate Sodium
No data available

Sodium benzoate
No data available
9. PHYSICAL AND CHEMICAL PROPERTIES

Magnesium stearate
No data available

Corn Starch
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: Acute toxicity following ingestion is not expected. Accidental ingestion may cause effects similar to those seen in clinical use.

Long Term: Animal studies indicate that this material may cause adverse effects on the heart, liver, lungs, central nervous system.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include fatigue, clumsy motion of limbs/trunk (ataxia), state of intense good feeling (euphoria), incoordination. Other less common effects include hallucinations, delirium, amnesia, addiction, impairment of motor and cognitive skills. The effects are reversible in nature. All observed adverse effects were consistent with the sedative action of this compound. Secreted in human breast milk.

Acute Toxicity: (Species, Route, End Point, Dose)

Triazolam

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>LD 50</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>&gt;5000 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>Oral</td>
<td>&gt;5,000 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>Intraperitoneal</td>
<td>&gt;5,000 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>Intraperitoneal</td>
<td>1,625 mg/kg</td>
<td></td>
</tr>
</tbody>
</table>
11. TOXICOLOGICAL INFORMATION

Microcrystalline cellulose
Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Sodium benzoate
Rat Oral LD50 4,070 mg/kg
Mouse Oral LD50 1600mg/kg

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Triazolam
Eye Irritation Rabbit Mild
Skin Irritation Rabbit No effect

Microcrystalline cellulose
Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Triazolam
1 Year(s) Dog Oral 3 mg/kg/day LOAEL Central nervous system, Liver
1 Year(s) Rat Oral 1 mg/kg/day NOAEL Liver, Lungs, Heart
2 Year(s) Rat Oral 0.5 mg/kg/day NOAEL None identified
3 Month(s) Dog Oral 100 mg/kg/day LOAEL Central Nervous System, Liver
3 Month(s) Rat Oral 300 mg/kg/day LOAEL Central Nervous System

Sodium benzoate
10 Day(s) Rat Oral 27370 mg/kg LOAEL Liver, Blood
10 Day(s) Mouse Oral 45 g/kg LOAEL Liver, Kidney, Blood, Ureter, Bladder

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Triazolam
Embryo / Fetal Development Rat Oral 30 mg/kg/day NOAEL Not teratogenic
Embryo / Fetal Development Rabbit Oral 30 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rabbit Oral 5 mg/kg/day LOAEL Not Teratogenic, Fetotoxicity

Sodium benzoate
Embryo / Fetal Development Rat Oral 44 g/kg LOEL Developmental toxicity,

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)
11. TOXICOLOGICAL INFORMATION

Triazolam
Bacterial Mutagenicity (Ames)  Bacteria  Negative
Direct DNA Damage  Not specified  Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Triazolam
2 Year(s)  Mouse  Oral, in feed  80  NOAEL  Not carcinogenic
2 Year(s)  Rat  Oral, in feed  100  NOAEL  Not carcinogenic

Carcinogen Status:  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

12. ECOLOGICAL INFORMATION

Environmental Overview:  Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:  No data available

Persistence and Degradability:  No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Triazolam
Predicted  7.4  Log D  8.175

Mobility in Soil:  No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:  Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

Triazolam
CERCLA/SARA 313 Emission reporting  Not Listed
California Proposition 65  developmental toxicity initial date 4/1/90
U.S. Drug Enforcement Administration:  Schedule IV Controlled Substance
Standard for the Uniform Scheduling for Drugs and Poisons:  Schedule 4
EU EINECS/ELINCS List  249-307-3

Lactose
CERCLA/SARA 313 Emission reporting  Not Listed
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
REACH - Annex IV - Exemptions from the obligations of Register:  Present
EU EINECS/ELINCS List  200-559-2

Microcrystalline cellulose
CERCLA/SARA 313 Emission reporting  Not Listed
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:  Use restricted. See item 9(f). powder
EU EINECS/ELINCS List  232-674-9

Silicon dioxide, NF
CERCLA/SARA 313 Emission reporting  Not Listed
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
Australia (AICS):  Present
EU EINECS/ELINCS List  231-545-4

Docusate Sodium
CERCLA/SARA 313 Emission reporting  Not Listed
California Proposition 65  Not Listed
Inventory - United States TSCA - Sect. 8(b)  Present
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Substance</th>
<th>Australia (AICS):</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium stearate</td>
<td>Not Listed</td>
<td>209-150-3</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>Not Listed</td>
<td>209-406-4</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children

Toxic to Reproduction: Category 2

R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision:
Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information.

Revision date: 03-Apr-2015
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.
End of Safety Data Sheet